title: Decay-accelerating factor in the periovulatory rat ovary.
abstract: One of the most prominent inflammatory reactions is the activation of the complement system. The activated complement system does not distinguish between pathogens and the host cell. In order to prevent autologous complement-mediated attack, host cells express a variety of both membrane-bound and fluid-phase complement regulatory proteins which control activity of the complement cascade by acting on convertase enzymes or the membrane-attack complex. Although the process of ovulation is facilitated by the inflammatory reaction, this reaction has the potential to cause serious damage to growing follicles, ovulated follicles, and other important ovarian tissues. This study was undertaken to characterize the expression and regulation of decay-accelerating factor (DAF), a complement regulator, as a potential mediator of ovarian tissue protection from ovulatory inflammation. DNA microarray and Northern blot analyses showed that an ovulatory gonadotropin stimulus dramatically yet transiently induced DAF mRNA expression in the immature rat ovary. Northern blot and PCR analyses revealed that of the three known DAF isoforms, glycosylphosphatidylinositol (GPI)-, soluble-, and transmembrane-(TM) DAF, GPI-DAF was the predominant form. In situ hybridization localized GPI-DAF mRNA expression in the theca-interstitial cells of the periovulatory ovary. Neither the anti-progestin RU486 nor the cyclooxygenase inhibitor indomethacin significantly inhibited human chorionic gonadotropin (hCG)-induced GPI-DAF mRNA expression in vivo. In vitro theca cell culture studies indicated that hCG induces GPI-DAF mRNA expression through the protein kinase A pathway. This study suggests that gonadotropin-induced GPI-DAF may be involved in the protection of ovarian tissues from the potential attack by the complement system activated by the inflammatory response associated with ovulation.
authors.affiliation: Department of Clinical Sciences and Biological Sciences, University of Kentucky, Lexington, Kentucky 40506, USA.
authors.forename: Mary C
authors.initials: MC
authors.lastname: Gieske
authors.forename: Gi Youn
authors.initials: GY
authors.lastname: Na
authors.forename: Yongbum
authors.initials: Y
authors.lastname: Koo
authors.forename: Misung
authors.initials: M
authors.lastname: Jo
authors.forename: Thomas E
authors.initials: TE
authors.lastname: Curry
authors.forename: Chemyong
authors.initials: C
authors.lastname: Ko
mesh_terms: D000818:Animals; D015152:Blotting, Northern; D018958:CD55 Antigens / Q000235:genetics / Q000378:metabolism*; D006063:Chorionic Gonadotropin / Q000494:pharmacology; D016861:Cyclooxygenase Inhibitors / Q000494:pharmacology; D005260:Female; D007213:Indomethacin / Q000494:pharmacology; D015735:Mifepristone / Q000494:pharmacology; D020411:Oligonucleotide Array Sequence Analysis; D010060:Ovulation / Q000502:physiology*; D011372:Progestins / Q000037:antagonists & inhibitors; D020033:Protein Isoforms / Q000235:genetics / Q000378:metabolism*; D012333:RNA, Messenger / Q000032:analysis*; D051381:Rats; D017207:Rats, Sprague-Dawley; D020133:Reverse Transcriptase Polymerase Chain Reaction; D013268:Stimulation, Chemical; D013799:Theca Cells / Q000737:chemistry*
chemical_list: D018958:CD55 Antigens; D006063:Chorionic Gonadotropin; D016861:Cyclooxygenase Inhibitors; D011372:Progestins; D020033:Protein Isoforms; D012333:RNA, Messenger; D015735:Mifepristone; D007213:Indomethacin